Laurus Labs Limited has informed the Exchange about General Updates
LAURUSLABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Laus Labs' Board approved the appointment of two new Independent Directors – Dr. Shekhar Chintamani Mande (former CSIR Director General, currently on Tata Steel board) and Ms. Sutapa Banerjee (wealth management veteran on boards of Godrej Properties, Polycab, Axis Capital) – each for a 5-year term starting July 2, 2026, subject to shareholder approval. The Board also noted the retirement of Mrs. Aruna Bhinge as Independent Director effective July 6, 2026, after completing her second 5-year term. Additionally, the company will invest up to €9.8 million (about ₹100+ crore equivalent) in its 49:51 joint venture KRKA Pharma Private Limited, with co-venturer KRKA d.d. (Slovenia) investing ~€10.2 million to fund a new manufacturing facility, keeping the shareholding ratio unchanged. Finally, the Board approved the voluntary closure of Laurus Generics GmbH (Germany), a step-down subsidiary with nil revenue and a negative networth of about €1.05 million, which the company said will have no material financial impact.
The director changes are routine governance refreshes with strong-profile independent additions, likely to be viewed positively. The KRKA investment signals continued commitment to the JV's manufacturing expansion, while the closure of the dormant German subsidiary is a non-event financially.